African American patients with gout: Efficacy and safety of febuxostat vs allopurinol

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Wells, Alvin F ^a   MacDonald, Patricia A ^b   Chefo, Solomon ^b   Jackson, Robert L ^b  

^a Rheumatology and Immunotherapy Center   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; FEBUXOSTAT; LANSOPRAZOLE; NAPROXEN; URATE; ANTIGOUT AGENT; THIAZOLE DERIVATIVE;

ADULT; AFRICAN AMERICAN; ARTHROPATHY; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GOUT; GOUT FLARE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OBESITY; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; ADOLESCENT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ETHNOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ALLOPURINOL; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; THIAZOLES; YOUNG ADULT;

EID: 84856767902     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-15     Document Type: Article

References (62)

1. Epidemiology of gout: is the incidence rising? Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE, J Rheumatol 2002 29 2403 2406 12415600 (Pubitemid 35266034)
2. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R, J Rheumatol 2004 31 1582 1587 15290739 (Pubitemid 39006641)
3. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, Arthritis Rheum 2008 58 26 35 10.1002/art.23176 18163497
4. United States Census Bureau. Table 3. Annual Estimates of the Resident Population by Sex, Race, and Hispanic Origin for the United States: April 1, 2000 to July 1, 2009 (NC-EST2009-03) 2010 Available at: http://www.census.gov/ popest/national/asrh/NC-EST2009-srh.html. Accessed February 14, 2011
5. Racial differences in the incidence of gout. The role of hypertension. Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ, Arthritis Rheum 1995 38 628 632 10.1002/art.1780380508 7748218
6. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F, Arthritis Rheum 1998 41 778 799 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V 9588729 (Pubitemid 28225778)
7. Gout in ambulatory care settings in the United States. Krishnan E, Lienesch D, Kwoh CK, J Rheumatol 2008 35 498 501 18260174 (Pubitemid 351374428)
8. National Center for Health Statistics. Health, United States, 2009: With special feature on medical technology. Hyattsville, MD: Centers for Disease Control. U.S. Department of Health and Human Services 2010
9. Effect of African American race on hypertension management: a real-world observational study among 28 US physician practices. Batson B, Belletti D, Wogen J, Ethn Dis 2010 20 409 415 21305830
10. Pathogenesis of gout. Choi HK, Mount DB, Reginato AM, Ann Intern Med 2005 143 499 516 16204163 (Pubitemid 41379398)
11. Clinical practice. Gout. Terkeltaub RA, N Engl J Med 2003 349 1647 1655 10.1056/NEJMcp030733 14573737 (Pubitemid 37303887)
12. We can make gout management more successful now. Becker MA, Chohan S, Curr Opin Rheumatol 2008 20 167 172 10.1097/BOR.0b013e3282f54d03 18349746 (Pubitemid 351339888)
13. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Shoji A, Yamanaka H, Kamatani N, Arthritis Rheum 2004 51 321 325 10.1002/art.20405 15188314 (Pubitemid 38725128)
14. Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C, J Rheumatol 2009 36 1273 1278 10.3899/jrheum.080814 19286847
15. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C, Rheumatology (Oxford) 2009 48 188 194
16. Gout: six-year follow-up on probenecid (benemid) therapy. Bartels EC, Matossian GS, Arthritis Rheum 1959 2 193 202 10.1002/1529-0131(195906)2: 3<193::AID-ART1780020302>3.0.CO;2-8 13662213
17. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW, Mayo Clin Proc 2006 81 925 934 10.4065/81.7.925 16835972 (Pubitemid 43993484)
18. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I, Ann Rheum Dis 2006 65 1312 1324 10.1136/ard.2006.055269 16707532 (Pubitemid 44620440)
19. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N, Kumar S, Stamp L, Gow P, J Rheumatol 2006 33 1646 1650 16783857 (Pubitemid 44168841)
20. ® Full Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals North America, Inc. 2011
21. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N, N Engl J Med 2005 353 2450 2461 10.1056/NEJMoa050373 16339094 (Pubitemid 41781828)
22. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N, Arthritis Rheum 2008 59 1540 1548 10.1002/art.24209 18975369
23. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Becker MA, Schumacher HR, Espinoza LR, Wells AF, Macdonald P, Lloyd E, Lademacher C, Arthritis Res Ther 2010 12 63 10.1186/ar2978 20370912
24. Preliminary criteria for the classification of the acute arthritis of primary gout. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF, Arthritis Rheum 1977 20 895 900 10.1002/art.1780200320 856219
25. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
26. Predictability of creatinine clearance estimates in critically ill patients. Robert S, Zarowitz BJ, Peterson EL, Dumler F, Crit Care Med 1993 21 1487 1495 10.1097/00003246-199310000-00016 8403957 (Pubitemid 23312482)
27. Genetic factors in drug metabolism. Belle DJ, Singh H, Am Fam Physician 2008 77 1553 1560 18581835
28. Genetic and clinical predictors of warfarin dose requirements in African Americans. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, Viana MA, Patel SR, Johnson JA, Clin Pharmacol Ther 2010 87 459 464 10.1038/clpt.2009.223 20072124
29. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C, J Pharmacol Exp Ther 2003 307 117 128 10.1124/jpet.103.054072 12944498 (Pubitemid 37151897)
30. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Kaniwa N, Kurose K, Jinno H, Tanaka-Kagawa T, Saito Y, Saeki M, Sawada J, Tohkin M, Hasegawa R, Drug Metab Dispos 2005 33 458 465 15572581 (Pubitemid 40279948)
31. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI, Mol Pharmacol 2001 60 382 387 11455026 (Pubitemid 32678304)
32. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS, Lancet 2008 372 1953 1961 10.1016/S0140-6736(08)61343-4 18834626
33. Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families. Rule AD, de Andrade M, Matsumoto M, Mosley TH, Kardia S, Turner ST, Rheumatology (Oxford) 2010
34. A genome-wide association study of serum uric acid in African Americans. Charles BA, Shriner D, Doumatey A, Chen G, Zhou J, Huang H, Herbert A, Gerry NP, Christman MF, Adeyemo A, Rotimi CN, BMC Med Genomics 2011 4 17 10.1186/1755-8794-4-17 21294900
35. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Krishnan E, Rheumatology (Oxford) 2010 49 1229 1238 10.1093/rheumatology/keq037
36. Altered uric acid levels and disease states. Kutzing MK, Firestein BL, J Pharmacol Exp Ther 2008 324 1 7 17890445 (Pubitemid 350294141)
37. Gout and the risk of acute myocardial infarction. Krishnan E, Baker JF, Furst DE, Schumacher HR, Arthritis Rheum 2006 54 2688 2696 10.1002/art.22014 16871533 (Pubitemid 44208638)
38. Current and future therapeutic options for the management of gout. Whelton A, Am J Ther 2010 17 402 417 20562597
39. High serum uric acid as a novel risk factor for type 2 diabetes. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC, Diabetes Care 2008 31 361 362 17977935 (Pubitemid 351213351)
40. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK, Ann Rheum Dis 2010 69 1162 1164 10.1136/ard.2009.122770 20124358
41. Independent impact of gout on mortality and risk for coronary heart disease. Choi HK, Curhan G, Circulation 2007 116 894 900 10.1161/CIRCULATIONAHA. 107.703389 17698728 (Pubitemid 47300913)
42. Long-term cardiovascular mortality among middle-aged men with gout. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, Arch Intern Med 2008 168 1104 1110 10.1001/archinte.168.10.1104 18504339 (Pubitemid 351749228)
43. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, Wofford MR, Herrington DM, Hypertension 2006 48 1037 1042 10.1161/01.HYP.0000249768.26560.66 17060502 (Pubitemid 44772705)
44. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. Fang J, Alderman MH, Jama 2000 283 2404 2410 10.1001/jama.283.18.2404 10815083 (Pubitemid 30257539)
45. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM, Arthritis Rheum 2006 55 786 790 10.1002/art.22232 17013833 (Pubitemid 44619193)
46. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A, Arthritis Rheum 2002 47 356 360 10.1002/art.10511 12209479 (Pubitemid 34856121)
47. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Perez-Ruiz F, Liote F, Arthritis Rheum 2007 57 1324 1328 10.1002/art.23007 17907217 (Pubitemid 47585481)
48. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ, Nephron Physiol 2008 108 69 78 10.1159/000127837 18434753 (Pubitemid 351704308)
49. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Zhao L, Johnson RJ, Nephrol Dial Transplant 2008 23 1179 1185 18048425 (Pubitemid 351767502)
50. Renal function in gout: long-term treatment effects of febuxostat. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L, J Clin Rheumatol 2011 17 7 13 21169856
51. Allopurinol treatment and its effect on renal function in gout: a controlled study. Gibson T, Rodgers V, Potter C, Simmonds HA, Ann Rheum Dis 1982 41 59 65 10.1136/ard.41.1.59 7039523 (Pubitemid 12136653)
52. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A, Int Urol Nephrol 2007 39 1227 1233 10.1007/s11255-007- 9253-3 17701281 (Pubitemid 350193621)
53. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Siu YP, Leung KT, Tong MK, Kwan TH, Am J Kidney Dis 2006 47 51 59 10.1053/j.ajkd.2005.10.006 16377385 (Pubitemid 41828266)
54. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Solomon DH, Avorn J, Levin R, Brookhart MA, Ann Rheum Dis 2008 67 609 613 17728328 (Pubitemid 351571922)
55. Ethnic health disparities in arthritis and musculoskeletal diseases: report of a scientific conference. Jordan JM, Lawrence R, Kington R, Fraser P, Karlson E, Lorig K, Liang MH, Arthritis Rheum 2002 46 2280 2286 10.1002/art.10480 12355474
56. National Healthcare Disparities Report. 2010 Agency for Healthcare Research and Quality. 2011, AHRQ Publication No. 11-0005. http://www.ahrq.gov/ qual/qrdr10.htm
57. The association between perceived provider discrimination, healthcare utilization and health status in racial and ethnic minorities. Lee C, Ayers SL, Kronenfeld JJ, Ethn Dis 2009 19 330 337 19769017
58. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L, Arthritis Rheum 2009 61 413 418 10.1002/art.24338 19333986
59. Racial disparities in treatment preferences for rheumatoid arthritis. Constantinescu F, Goucher S, Weinstein A, Fraenkel L, Med Care 2009 47 350 355 10.1097/MLR.0b013e31818af829 19165120
60. Understanding ethnic disparities in the use of total joint arthroplasty: application of the health belief model. Ang DC, Monahan PO, Cronan TA, Arthritis Rheum 2008 59 102 108 10.1002/art.23243 18163395 (Pubitemid 351171884)
61. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N, Nucleosides Nucleotides Nucleic Acids 2008 27 585 591 10.1080/15257770802136032 18600509 (Pubitemid 351948555)
62. A perspective on African American participation in clinical trials. Shaya FT, Gbarayor CM, Huiwen Keri Y, Agyeman-Duah M, Saunders E, Contemp Clin Trials 2007 28 213 217 10.1016/j.cct.2006.10.001 17141575 (Pubitemid 44937882)